Test the next level of deliverability with Orsiro Mission

call out

Outstanding patient outcomes3​​​​​​​


Outstanding patient outcomes3​​​​​​​

∆ Posterior probability of superiority in STEMI in c​​​​​​​omparison to Xience at 24-months in the BIOSTEMI trial, with respect to TLF, based on combined data set of BIOSTEMI and BIOSCIENCE STEMI groups. ∆∆ In comparison to Xience based on BIOFLOW-V 5-year results. 

​​​​​​​*Based on TLF rates. **Based on BIOFLOW-V 5-year results compared to Xience (p=0.021). 

1. In comparison to Xience Sierra, Resolute Onyx and Synergy for bench tests on pushability, trackability and crossability, BIOTRONIK data on file; 2. As characterized with respect to strut thickness in Bangalore et al. Meta-analysis; 3. Based on investigator’s interpretation of BIOFLOW-V primary endpoint results; 4. BIOTRONIK data on file, status January 2020. 5. Pilgrim et al. Biodegradable – versus durable-polymer drug-eluting stents for STEMI. Final 2-year outcomes of the BIOSTEMI trial. J Am Coll Cardiol. Cardiovasc Interven. 2021, doi: 10.1016/j.jcin.2020.12.011.

Orsiro and Orsiro Mission are trademarks or registered trademarks of the BIOTRONIK Group of Companies.

Disclaimer​​​​​​​                                                                                                                                                                                                    Clinical data conducted with Orsiro, Orsiro Mission’s predecessor device can be used to illustrate Orsiro Mission clinical outcomes. 

© 2022 BIOTRONIK AG – All rights reserved.                                                                                                                                Specifications are subject to modification, revision and improvement.